Dendritic Cell Clinical Trials

2 recruiting

Dendritic Cell Trials at a Glance

15 actively recruiting trials for dendritic cell are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Seattle, Boston, and Pittsburgh. Lead sponsors running dendritic cell studies include Fred Hutchinson Cancer Center, Chongqing Precision Biotech Co., Ltd, and Dana-Farber Cancer Institute.

Browse dendritic cell trials by phase

Treatments under study

About Dendritic Cell Clinical Trials

Looking for clinical trials for Dendritic Cell? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dendritic Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dendritic Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center40 enrolled1 locationNCT04216524
Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute200 enrolled20 locationsNCT05430971
Recruiting
Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Chronic Myeloid LeukemiaMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics130 enrolled7 locationsNCT05362773
Recruiting
Early Phase 1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Myelodysplastic Syndromes (MDS)Precursor Cell Lymphoblastic Leukemia-LymphomaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic18 enrolled1 locationNCT06765876
Recruiting
Phase 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute72 enrolled3 locationsNCT03113643
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting

International Rare Histiocytic Disorders Registry (IRHDR)

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more
The Hospital for Sick Children400 enrolled15 locationsNCT02285582
Recruiting
Phase 1

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd30 enrolled1 locationNCT06690827
Recruiting
Phase 2

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Neoantigen-loaded Dendritic Cell VaccineImmune Checkpoint Inhibitors (ICIs)
Sichuan University165 enrolled1 locationNCT06675201
Recruiting
Phase 4

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

AgingVaccine ResponseInfluenza Vaccine+1 more
The Jackson Laboratory75 enrolled1 locationNCT05518500
Recruiting
Phase 1Phase 2

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid LeukemiaRefractory LeukemiaRelapse Leukemia+1 more
Chongqing Precision Biotech Co., Ltd36 enrolled1 locationNCT06006403
Recruiting
Phase 1

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

ImmunotherapyMyelodysplastic SyndromesDendritic Cell+1 more
Affiliated Hospital to Academy of Military Medical Sciences40 enrolled1 locationNCT04999943